Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon (Nasdaq: ANNX) granted equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Annexon (Nasdaq: ANNX) granted equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4). The awards cover options for 243,000 shares at a $5.21 exercise price, with a ten-year term and four-year vesting schedule.

Argus May 19 session

-1.01% close to close Open Argus

Details

News Market Reaction – ANNX

On May 19, the first trading day after this news, ANNX closed 1.01% below the previous close.

Data tracked by StockTitan Argus for the May 19 session.

Market Context

This announcement details routine inducement stock option grants to new employees under Annexon’s 20...

Analysis

This announcement details routine inducement stock option grants to new employees under Annexon’s 2022 Employment Inducement Award Plan, with 243,000 shares granted at a $5.21 exercise price and standard four-year vesting. In recent months, the company has emphasized late-stage neuroinflammatory programs and reported cash of $225.0 million as of March 31, 2026, supporting runway into the second half of 2027. Investors may continue watching upcoming Phase 3 data and planned regulatory filings as the primary catalysts.

Key Figures

New employees: 3 employees Inducement plan year: 2022 Option shares granted: 243,000 shares +5 more

New employees

3 employees

Recipients of inducement equity awards

Inducement plan year

2022

2022 Employment Inducement Award Plan

Option shares granted

243,000 shares

Aggregate options to new non-executive employees

Option term

10 years

Term of inducement stock options

Exercise price

$5.21 per share

Equal to ANNX closing price on May 15, 2026

Vesting period

4 years

Inducement options vest over four years

Initial cliff vesting

25% at 1 year

25% of shares vest on first anniversary

Ongoing vesting rate

1/48th monthly

Remaining options vest monthly thereafter

Historical Context

5 past events · Latest: May 07

5 events

1. May 07

   Q1 2026 earnings

   24h Move

   +3.1%

   Quarterly results with portfolio progress and cash runway into H2 2027.

2. May 06

   Conference presentation

   24h Move

   -0.3%

   Announcement of Bank of America healthcare conference presentation and webcast.

3. Apr 08

   Conference appearance

   24h Move

   +1.5%

   Needham virtual healthcare conference presentation and webcast availability.

4. Mar 30

   FY 2025 earnings

   24h Move

   +11.7%

   Year-end 2025 results with strong cash position and 2026 milestones.

5. Mar 16

   Inducement grant

   24h Move

   -1.9%

   Single-employee inducement option grant under 2022 plan with standard vesting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the new non-executive employees received options to purchase 243,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $5.21, which was the closing price of Annexon’s common stock on May 15, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did Annexon (ANNX) announce on May 18, 2026?

Annexon announced stock option inducement grants for three new non-executive employees. According to Annexon, these options cover 243,000 shares of common stock under the 2022 Employment Inducement Award Plan, awarded in line with Nasdaq Listing Rule 5635(c)(4).

How many Annexon (ANNX) shares are covered by the new employee stock options?

The new inducement awards cover options to purchase 243,000 Annexon common shares. According to Annexon, these options were granted to three non-executive employees as part of its 2022 Employment Inducement Award Plan and are intended to support employee recruitment and retention.

What is the exercise price and term of the new Annexon (ANNX) stock options?

The options have a ten-year term and an exercise price of $5.21 per share. According to Annexon, $5.21 represents the closing price of its common stock on May 15, 2026, the official grant date for these inducement stock option awards.

How do the new Annexon (ANNX) inducement options vest for employees?

The inducement options vest over four years with a standard schedule. According to Annexon, 25% of the shares vest on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the next three years, contingent on continued service.

Why were Annexon (ANNX) inducement grants made under Nasdaq Listing Rule 5635(c)(4)?

The grants were structured as inducement awards to comply with Nasdaq Listing Rule 5635(c)(4). According to Annexon, this rule allows equity awards to new employees outside shareholder-approved plans when used as a material inducement to accept employment with the company.